Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Australia.
Department of Immunology, Sir Charles Gairdner Hospital, Nedlands, Australia.
J Neuroimmunol. 2018 Oct 15;323:119-124. doi: 10.1016/j.jneuroim.2018.06.013. Epub 2018 Jul 24.
Antibodies against glutamic acid decarboxylase (GAD) are reported in association with numerous neurological conditions including temporal lobe epilepsy and limbic encephalitis. We report a case of Anti-GAD-Antibody associated encephalitis presenting with epilepsia partialis continua (EPC) progressing to a fulminant encephalopathy preferentially affecting the frontal lobes associated with coma and refractory status epilepticus. The abnormalities identified on MRI included marked bilateral frontal lobe involvement which has not been reported in other auto-immune encephalitides and may be specific for Anti-GAD-Antibody associated encephalitis. Similar to the majority of cases of Anti-GAD associated neurological disturbance no underlying malignancy was identified. Treatment with high dose corticosteriods, IVIG and plasmapheresis had minimal response, but escalation of treatment with rituximab and cyclophosphamide was associated with clinical improvement, reducing antibody titers and resolution of MRI changes.
谷氨酸脱羧酶 (GAD) 抗体与许多神经疾病有关,包括颞叶癫痫和边缘性脑炎。我们报告了一例抗 GAD 抗体相关脑炎,表现为部分连续性癫痫 (EPC) 进展为暴发性脑病,主要影响额叶,伴有昏迷和难治性癫痫持续状态。MRI 上发现的异常包括显著的双侧额叶受累,这在其他自身免疫性脑炎中尚未报道,可能是抗 GAD 抗体相关脑炎的特异性表现。与大多数抗 GAD 相关神经功能障碍的病例一样,未发现潜在的恶性肿瘤。大剂量皮质类固醇、IVIG 和血浆置换治疗反应甚微,但用利妥昔单抗和环磷酰胺升级治疗与临床改善相关,降低抗体滴度并解决 MRI 变化。